Skip to main content

Table 1 Estimates of SpikeVax™ vaccine efficacy against infection, symptomatic disease, and severe disease caused by the original and Alpha variants of SARS-CoV-2 virus [25,26,27,28,29]

From: Impact of non-pharmaceutical interventions and vaccination on COVID-19 outbreaks in Nunavut, Canada: a Canadian Immunization Research Network (CIRN) study

Efficacy against (%) Infection
(95% CI)
Symptomatic infection
(95% CI)
Severe disease
(95% CI)
Variant 14 d after dose 1 7 d after dose 2 14 d after dose 1 7 d after dose 2 14 d after dose 1 7 d after dose 2
Original 61 (31—79) 93.3 (85.7—97.4) 92.1 (68.8—99.1) 94.1 (89.3—96.8) 92.1 (68.8—99.1) 100
Alpha 54.7 (44.8—62.9) 86 (81—90.6) 88.1 (83.7—91.5) 91 (84—95) 81.6 (71.0—88.8) 95.7 (73.4—99.9)